{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-102170","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.582442+00:00","generated_at":"2026-05-15T15:07:56.415572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya reports FY2025 net loss of $90.6M; cash runway into H2 2027","bullets":["Net loss $90.6M ($0.59/share) for FY2025 vs $111.1M ($1.31) in FY2024; Q4 net loss $20.2M.","Cash, equivalents and investments $100.5M at Dec 31, 2025; December offering net $55.8M plus Alnylam upfront extend runway into H2 2027.","TN-201 (HCM) and TN-401 (ARVC) gene therapies: interim data presented; enrollment resumed; plans for regulatory alignment in 2026.","Entered multi-target collaboration with Alnylam: $10M upfront, up to $1.1B milestones; Alnylam handles development and commercialization.","TN-301 (HDAC6i) preclinical DMD data: improved grip strength to wild-type levels at 3 mg/kg, outperforming givinostat."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-102170","json":"https://secwatch.observer/filing/0001193125-26-102170.json","markdown":"https://secwatch.observer/filing/0001193125-26-102170.md","text":"https://secwatch.observer/filing/0001193125-26-102170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/0001193125-26-102170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/tnya-20260311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:07:56.415572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}